brexit-istock-537519806_andrewlinscott
andrewlinscott / iStockphoto.com
16 November 2018Big Pharma

Brexit draft deal: a welcome step but more certainty needed, say lawyers

While the pharmaceutical industry has welcomed the draft Withdrawal Agreement for the UK’s departure from the EU, more clarity is still needed, lawyers have told LSIPR.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
19 July 2017   The Association of the British Pharmaceutical Industry and seven other UK and European life sciences bodies have jointly written to the UK and EU Brexit negotiators.
Big Pharma
12 November 2018   Associations representing the pharmaceutical and biotechnology fields have said that the UK should maintain “close cooperation” with the EU post-Brexit, to ensure that access to safe and effective medicines continues in both markets.

More on this story

Big Pharma
19 July 2017   The Association of the British Pharmaceutical Industry and seven other UK and European life sciences bodies have jointly written to the UK and EU Brexit negotiators.
Big Pharma
12 November 2018   Associations representing the pharmaceutical and biotechnology fields have said that the UK should maintain “close cooperation” with the EU post-Brexit, to ensure that access to safe and effective medicines continues in both markets.

More on this story

Big Pharma
19 July 2017   The Association of the British Pharmaceutical Industry and seven other UK and European life sciences bodies have jointly written to the UK and EU Brexit negotiators.
Big Pharma
12 November 2018   Associations representing the pharmaceutical and biotechnology fields have said that the UK should maintain “close cooperation” with the EU post-Brexit, to ensure that access to safe and effective medicines continues in both markets.